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SUMMARY
Objectives: To determine the pattern and risk factors for retinal
vein occlusion at the Guinness Eye Center, Onitsha,
Nigeria.
Materials and Methods: Case files of all patients with retinal
vein occlusion between May 1997 and April 2004 were
reviewed. Information on age, sex, visual acuity, ocular
complications and associated risk factors were abstracted
into a standard proforma and analysed.
Results: 45 patients (48 eyes) were seen with a mean age of 58
years; range - 41-77 years. There were 16 (35.6%) male
patients and 29(64.4%) female patients. Thirty-eight
(84.4%) patients (40 eyes) had central retinal vein
occlusion (CRVO), 7 (15.6%) patients (8 eyes) had branch
vein occlusion (BRVO), and 29 (60.4%) eyes (all CRVO)
had ischaemic vein occlusion. Twenty-eight (58.3%) eyes
were blind, while 18 (37.5%) had visual impairment.
Twenty-five (55.6%) patients had hypertension, 10
(22.2%) were diabetic and 10 (22.2%) had glaucoma. 
Conclusions: Retinal vein occlusion is an important retinal
vascular disease that causes visual loss. The incidence of the
disease could be reduced if the associated risk factors were
detected and treated early. A prospective study was carried
out to clearly identify the modifiable risk factors for the
disease in our environment.
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INTRODUCTION
Retinal vein occlusion is a retinal vascular disorder with
potentially blinding complications. Worldwide, central
retinal vein occlusion along with branch retinal vein
occlusion constitute the second commonest retinal vascular
disease, after diabetic retinopathy.  Reports on eye diseases1,2
from different parts of Nigeria have documented the
contribution of retinal vein occlusion to ocular morbidity.3-5
Abiose  and Ayanru,  in earlier studies, separately reported3 4
the rarity of retinal vascular diseases, including retinal vein
occlusion in Nigeria. A hospital-based study in Anambra
State, however, showed that retinal vein occlusion
constitutes 12.5% of retinal diseases.5
During the period under review, the management of
retinal vein occlusion at the Guinness Eye Center consisted
of prescribing low doses of aspirin in the hope of decreasing
blood platelet aggregation; and treatment of any known
systemic and or ocular disease known to predispose to the
disease. Laboratory investigations were limited to packed
cell volume and platelet counts, as the centre’s laboratory at
that time lacked the capacity to estimate serum lipids and
cholesterol. Facilities for fluorescein angiography and laser
treatment were not available. 
This study was aimed at determining the pattern and
possible risk factors for retinal vein occlusion at a tertiary
eye centre, as data on this important disease in Nigeria is
scarce.
MATERIALS AND METHODS
This is a retrospective study. The case files of all consecutive
new patients with retinal vein occlusion seen at the
Guinness Eye Center, Onitsha over a 7-year-period (May
1997 – April 2004) were reviewed. 
Information on age; gender; habits; visual acuity;
clinical diagnosis, including type of vein occlusion, ocular
complications, and ocular and systemic risk factors were
abstracted into a standard proforma and analysed.
Blindness was defined as visual acuity <3/60, while acuity
<6/18 – 3/60 was regarded as visual impairment.
RESULTS
During the 7-year period, 43 new patients (48 eyes) with
retinal vein occlusion were seen. Five patients had bilateral
disease. The age range of the patients was 41–77 years; with
a median of 66 years and a mean of 58 years (table 1). There
were 17 (39.5%) male and 26 (60.5%) female patients.
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Twenty patients (46.5%) sniffed tobacco powder (‘snuff’)
while 8 (18.6%) drank alcohol. The time interval from the
onset of symptoms to presentation at the hospital ranged
from 1 to 18 months with a mean of 5 months.
Table 1. Age and sex distribution
Age (Years) M F Total %
41-50 2 6 8 18.6
51-60 5 3 8 18.6
61-70 8 10 18 41.9
$71 2 7 9 20.9
Total 17 26 43 100.0
Thirty-six patients (83.7%) had central retinal vein
occlusion (CRVO), while branch retinal vein occlusion
(BRVO) occurred in 7 patients (16.3%). Bilateral disease
occurred in 4 patients with CRVO and in a patient with
BRVO. Thus, a total of 48 eyes of 43 patients had retinal vein
occlusion. In 29 eyes (60.4%), the disease was ischemic. All
the ischemic cases occurred in CRVO patients.
The presenting visual acuity ranged from 6/12 to NPL
(table 2). Eighteen eyes (37.5%) had visual impairment and
28 eyes (58.3%) were blind. Twenty-two of the 28 (78.6%)
blind eyes had ischemic vein occlusion. The 2 blind eyes
with acuity of no light perception (NPL) had neovascular
glaucoma secondary to rubeosis iridis and angle
neovascularization.











Chronic simple glaucoma was co-existent in 10 patients
(23.2%); diabetes mellitus in 10 patients (23.2%); and
hypertension in 25 patients (58.1%). While 29 patients
(67.4%) did not keep more than one follow up appointment,
13 (30.2%) failed to keep any follow up appointment at all.
DISCUSSION
The results of this study show that retinal vein occlusion is
an important cause of low vision among the afflicted in our
hospital. There were more female patients among the study
cohort. Hospital-based studies are affected by selection bias.
Records show that more adult females than adult males
usually consult at the Guinness Eye Center, Onitsha. All the
patients in this cohort were adults. The female
preponderance in this cohort may be a reflection of the
pattern of attendance at the hospital. 
On the other hand, oral contraceptives are known to
predispose users to vein occlusion.  Women are more likely6
to use oral contraceptives and hormone replacement
therapy. However, the use of these drugs was not
documented in any of our patients. A prospective study is
required to better define the role of such drugs in the
aetiology of vein occlusion in Nigerians.
Glaucoma, found in 23.2% of our patients, could
predispose to vein occlusion.  Conversely, ischemic central1
retinal vein occlusion is a cause of neovascular glaucoma.1
Hypertension and diabetes mellitus were the two systemic
risk factors for the disease recorded in our patients. A study
in a major teaching hospital in the United States of America
reported that patients with retinal vein occlusion also had a
higher incidence of hypertension and diabetes mellitus.  The7
course of these ocular and systemic risk factors could be
modified by treatment. Therefore, vigorous treatment of the
ocular and systemic risk factors is recommended as a way of
perhaps preventing the occurrence of the disease. Nearly
half of our patients take snuff, a mixture of tobacco and
potash powder. The possible role of this powdery mixture
in the aetiology of retinal vein occlusion is at present not
clear and requires further study. 
This study was limited by the lack of facilities for
fluorescein angiography in our hospital. The advantages of
fluorescein angiography in the treatment of these patients
include clearly defining the areas of ischemia, determining
the rate of blood flow through retinal vessels, better
detection of macula oedema, and improved monitoring of
treatment outcome.  The Central Retinal Vein Occlusion8,9,10
Study recommends laser treatment when there is at least 10
disc areas of retinal nonperfusion. In our hospital, the
diagnosis of ischemic vein occlusion is made on clinical
grounds using such parameters as relative afferent
pupillary defect. It is therefore difficult to objectively
determine the number of disc areas of capillary
nonperfusion. 
More recent advances include the use of optical
coherent tomography in the diagnosis and in monitoring the
treatment outcome of macular oedema.  McAllister and11
Constable recommended laser-induced chorioretinal
anastomosis for the treatment of perfused central retinal
vein occlusion.  The intravitreal injection of triamcinolone12
acetonide has recently been found to be useful in the
treatment of macula oedema, especially the refractory
type.  Neither laser photocoagulation nor intravitreal13
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steroids was used on our patients, as they were not
available during the period under review. 
Another limitation of the study is the high default rate
among the patients. This prevented us from determining the
final visual outcome, the full impact on the burden of
blindness, and the natural history of retinal vein occlusion
among Nigerians. Loss of a high percentage of patients to
follow up has been a source of concern to many workers in
Nigeria, and the Guinness Eye Center is not exempt. In the
case of retinal vein occlusion patients, the lack of facilities
for proven effective treatment may have contributed to the
problem of default. Nevertheless, retinal vein occlusion as a
cause of low vision and blindness is well demonstrated in
this study in which none of the affected eyes had visual
acuity better than 6/12 and more than 58% of the eyes were
blind when first seen at the hospital. 
In conclusion, the incidence of retinal vein occlusion in
our hospital is relatively low; and central retinal vein
occlusion is more common. Women are more likely to be
affected than men. Based on presenting visual acuity, the
disorder impacts negatively on vision, increasing low vision
and blindness, albeit mainly uniocular. Patients, therefore,
need to be educated on the nature of the disease, including
the known risk factors and the natural history. The need to
provide facilities for the investigation and effective
treatment of the disease cannot be overemphasized.
Finally, a prospective study is required to further define
the epidemiological and clinical characteristics of patients
with retinal vein occlusion in our environment.
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